Andrew (Andy) Johnson, Ph.D., M.S.
About Andrew (Andy) Johnson, Ph.D., M.S.
Andrew (Andy) Johnson, Ph.D., M.S., is a Senior Medical Science Liaison at Bristol Myers Squibb with over 8 years of experience in Medical Affairs, specializing in Neuroscience, Nephrology, Transplant, and Cardiovascular therapeutic areas.
Company
Andrew Johnson is currently employed at Bristol Myers Squibb as a Senior Medical Science Liaison. He supports the Neurology/Neuroscience therapeutic area, with a particular focus on multiple sclerosis. He manages the portfolio for ZEPOSIA® (Multiple Sclerosis) and other pipeline assets. His territory encompasses the states of Iowa, Kansas, Missouri, and Nebraska. Bristol Myers Squibb is known for its leading role in biopharmaceutical innovations.
Title
Andrew Johnson holds the title of Senior Medical Science Liaison at Bristol Myers Squibb. In this capacity, he leverages his extensive background in Neuroscience, Nephrology, Transplant, and Cardiovascular therapeutic areas. His role involves clinician education, operational excellence, and managing a territory that includes Iowa, Kansas, Missouri, and Nebraska.
Education and Expertise
Andrew Johnson completed his Postdoctoral education in Neuroscience and Cerebrovascular Biology at Washington University School of Medicine in St. Louis from 2012 to 2014. He earned his Doctor of Philosophy in Pharmacology from the University of Iowa between 2006 and 2012. He also holds a Master of Science in Biochemistry and Biotechnology, and a Bachelor of Science in Biology (Major) and Chemistry (Minor) from the University of Missouri-Saint Louis, completed between 2001 and 2006. His academic background provides a robust foundation for his role in Medical Affairs.
Background
Before joining Bristol Myers Squibb, Andrew Johnson worked at several notable organizations. He was a Medical Science Liaison, Associate Director at Novartis from 2017 to 2021. Prior to that, he served as a Medical Science Liaison at Mallinckrodt Pharmaceuticals from 2014 to 2015 and again from 2016 to 2017. He also worked in similar roles at New Haven Pharmaceuticals, Inc. and the Department of Neurological Surgery at Washington University School of Medicine. Additionally, he has experience as a Lecturer and Instructor at the University of Iowa.
Achievements
Andrew Johnson has received several accolades for his work in Medical Affairs. Notably, he won the 'President’s Award for MSL of the Year' in 2020 within the Novartis Neuroscience Business Unit. He was also recognized with the 'WinAsOne Award' in 2021, a commercial-peer-nominated accolade at Novartis. These awards highlight his dedication to clinician education, strategic activities, and innovation within the medical field.